Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ArcticZymes Technologies ASA ( (DE:B4V) ) has shared an announcement.
ArcticZymes Technologies reported a 24% year-over-year increase in total revenues for Q3 2025, driven by strong performance in both its Biomanufacturing and Molecular Tools segments. The company also announced an exclusive European partnership with Brenntag, aimed at expanding its market reach and strengthening its position in the biomanufacturing sector, which is expected to enhance long-term growth and market penetration in Europe.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes for molecular research, In Vitro Diagnostics (IVD), and biomanufacturing. The company is listed on the Oslo Stock Exchange and is headquartered in Tromsø, Norway.
Average Trading Volume: 47,559
Current Market Cap: NOK1.42B
Find detailed analytics on B4V stock on TipRanks’ Stock Analysis page.